EDITAS MEDICINE, INC. (EDIT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$18.55M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$25.00M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$24.55M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$51.54M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$18.55M | (m) | $11.89M | (m) | $106.00K* | -$29.57M* | (m) | $20.18M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$25.00M | (m) | $2.83M | (m) | $92.00K | -$23.06M | (m) | $17.60M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$24.55M | (m) | $7.54M | (m) | $433.00K* | -$30.84M* | (m) | $19.77M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$51.54M | (m) | $3.58M | (m) | $0.00* | -$50.21M* | (m) | $16.18M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$76.16M | (m) | $4.66M | (m) | $114.00K | -$47.80M | (m) | $26.59M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$65.67M | (m) | $61.00K | (m) | $2.92M* | -$52.59M* | (m) | $47.64M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$71.90M | (m) | $513.00K | (m) | $3.49M* | -$57.06M* | (m) | $54.21M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$66.99M | (m) | $1.14M | (m) | $1.87M | -$49.87M | (m) | $48.79M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$50.16M | (m) | $5.34M | (m) | $239.00K* | -$35.46M* | (m) | $40.51M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$44.09M | (m) | $2.89M | (m) | $1.33M* | -$38.71M* | (m) | $29.78M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$50.96M | (m) | $9.85M | (m) | $1.84M | -$35.77M | (m) | $37.80M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$57.52M | (m) | $42.00K | (m) | $614.00K* | -$48.00M* | (m) | $41.33M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$54.23M | (m) | $6.36M | (m) | $632.00K* | -$37.84M* | (m) | $43.66M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$50.75M | (m) | $6.77M | (m) | $2.25M | -$49.23M | (m) | $37.98M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$39.25M | (m) | $6.20M | (m) | $2.34M* | -$40.78M* | (m) | $29.27M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$55.40M | (m) | $379.00K | (m) | $2.70M* | -$38.96M* | (m) | $33.75M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$56.88M | (m) | $6.50M | (m) | $84.00K | -$49.48M | (m) | $41.94M | (m) | (m) |
| 2020-09-30 | Reported | (m) | $8.99M | (m) | $62.84M | (m) | $1.79M* | -$54.80M* | (m) | $33.92M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$31.34M | (m) | $10.75M | (m) | $1.84M* | -$30.86M* | (m) | $28.01M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$46.62M | (m) | $5.72M | (m) | $2.15M | -$54.09M | (m) | $34.57M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$34.59M | (m) | $3.85M | (m) | $2.25M* | -$26.88M* | (m) | $22.70M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$35.65M | (m) | $2.33M | (m) | $1.51M* | -$25.81M* | (m) | $23.57M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$31.26M | (m) | $2.07M | (m) | $718.00K | -$29.00M | (m) | $15.84M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$26.25M | (m) | $6.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$16.26M | (m) | $14.52M | (m) | $938.00K* | -$7.84M* | (m) | $17.44M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$39.66M | (m) | $7.37M | (m) | $1.39M* | -$16.73M* | (m) | $32.72M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$31.56M | (m) | $3.93M | (m) | $1.01M | -$22.46M | (m) | $21.30M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$26.75M | (m) | (m) | (m) | $752.00K* | -$27.98M* | (m) | $20.40M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$26.11M | (m) | (m) | (m) | $362.00K* | -$26.16M* | (m) | $17.32M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$30.63M | (m) | (m) | (m) | $656.00K | $69.79M | (m) | $19.02M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$21.16M | (m) | (m) | (m) | $713.00K* | -$17.04M* | (m) | $10.83M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$19.20M | (m) | (m) | (m) | $1.16M* | (m) | (m) | $10.43M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$17.84M | (m) | (m) | (m) | $943.00K | (m) | (m) | $8.88M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$7.38M | (m) | (m) | (m) | $190.00K* | (m) | (m) | $3.85M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$10.40M | (m) | (m) | (m) | $535.00K* | (m) | (m) | $7.28M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$5.16M | (m) | (m) | (m) | $305.00K | (m) | (m) | $1.89M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$160.01M | (m) | $40.52M | (m) | $607.00K | -$165.24M | (m) | $89.95M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$251.15M | (m) | $32.31M | (m) | $8.83M | -$210.28M | (m) | $199.25M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$169.18M | (m) | $78.12M | (m) | $4.72M | -$132.18M | (m) | $177.65M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$225.95M | (m) | $19.71M | (m) | $4.12M | -$177.35M | (m) | $174.96M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$193.15M | (m) | $25.54M | (m) | $7.98M | -$163.80M | (m) | $142.51M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$134.84M | (m) | $90.73M | (m) | $7.16M | -$179.84M | (m) | $158.00M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$140.92M | (m) | $20.53M | (m) | $6.17M | -$40.67M | (m) | $96.90M | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$127.75M* | (m) | $14.37M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$109.42M* | (m) | $25.04M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$113.43M* | (m) | $30.08M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$113.73M | (m) | $31.94M | (m) | $4.75M | -$45.71M | (m) | $90.65M | (m) | (m) |
| 2018-12-31 | Rolling | (m) | -$113.73M* | (m) | $31.94M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$119.93M | (m) | $13.73M | (m) | $2.06M | -$9.42M | (m) | $83.16M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$97.19M | (m) | (m) | (m) | $3.49M | -$50.25M | (m) | $56.98M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$35.31M | (m) | (m) | (m) | $1.43M | -$5.44M | (m) | $18.85M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$12.72M | (m) | (m) | (m) | $1.22M | (m) | (m) | $5.07M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |